ENLV.US Enlivex Therapeutics Ltd

Healthcare Software USA Stocks
1.19 USD
Close of Nov 14, 2026
1.18 316.80
Market cap
USD 1.82M
P/E
0.0x
P/B
0.00x
ROE
147.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ENLV.US undervalued?

Graham number

The Graham number of Enlivex Therapeutics Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Enlivex Therapeutics Ltd fundamental analysis

No fundamental analysis for Enlivex Therapeutics Ltd yet.

Enlivex Therapeutics Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Enlivex Therapeutics Ltd

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failur…

Full company profile